Here are the DEF 14A proxy statements from ALX Oncology Holdings Inc. (ALXO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX Oncology Holdings Inc. is holding its 2026 annual meeting of stockholders as a virtual-only webcast on June 10, 2026 at 1:00 p.m. Pacific Time. Stockholders of record as of April 15, 2026, when 134,559,917 common shares were outstanding, may attend online, submit questions and vote.
Investors will vote on electing three Class III directors until 2029, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The proxy also outlines board structure, director independence, committee roles, executive compensation philosophy and how to submit future stockholder proposals or director nominations.